Dr. Di Costanzo on the Effectiveness of Sorafenib in HCC

Giovan Giuseppe Di Costanzo, MD
Published: Wednesday, May 24, 2017



Giovan Giuseppe Di Costanzo, MD, Cardarelli Hospital, discusses a scoring system to predict the effectiveness of sorafenib (Nexavar) in hepatocellular carcinoma (HCC).

The scoring system was constructed to improve the therapeutic strategy for HCC, states Di Constanzo. For patients with advanced HCC the only approved treatment remains to be sorafenib, which is not effective in all patients.

There have been many studies aimed towards investigating ways to determine which patients will see positive results with sorafenib, states Di Costanzo.
 


Giovan Giuseppe Di Costanzo, MD, Cardarelli Hospital, discusses a scoring system to predict the effectiveness of sorafenib (Nexavar) in hepatocellular carcinoma (HCC).

The scoring system was constructed to improve the therapeutic strategy for HCC, states Di Constanzo. For patients with advanced HCC the only approved treatment remains to be sorafenib, which is not effective in all patients.

There have been many studies aimed towards investigating ways to determine which patients will see positive results with sorafenib, states Di Costanzo.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x